Company intelligence / Profile preview

GENinCode

Oxford, England, United Kingdomgenincode.com ↗

Ownership: Private
Development stage: Commercial

Overview

GENinCode’s products are commercially available for advanced cardiovascular risk assessment using genetic and clinical data. The company has over fifteen years of R&D experience with a strong IP portfolio. Its tests are used to inform preventive care pathways but no interventional therapeutics or drug candidates are reported.

Therapeutic areas: CardiovascularNeurologyHematology
Modalities: Diagnostic test (genetic testing)Device (diagnostic platform)Software (AI-based risk assessment tools)
Industry: Molecular Diagnostics

Partnerships

Not explicitly listed; collaborations with leading institutions and key opinion leaders mentioned.

Beyond the preview

Go deeper on GENinCode.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GENinCode.

Explore the full profile